Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Treatment with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle ... stem cell transplant procedure. The BEAM-101 edit is designed to inhibit the ...

Maxcyte's technology helped Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) to develop the world's first FDA-approved gene-editing treatment for sickle cell ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Sickle cell disease is caused by abnormally shaped red blood cells ... The therapy works by editing the patient’s BCL11A gene to reactivate fetal haemoglobin production, preventing red blood cells ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

Researchers at the New York Blood Center have made a breakthrough in understanding the body’s autoimmune response to sickle ...